查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447729

药物筛选市场评估：按成分、样本类型、最终用户和地区划分的机会和预测（2017-2031）

Drug screening Market Assessment, By Components, By Sample Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5个工作天内

价格

全球药物筛选市场规模将从2023年的70.2亿美元成长到2031年的209.6亿美元，2024-2031年预测期间复合年增长率为14.65%，预计规模将持续成长。

全球药物筛检市场的成长是由酒精和药物消费的增加、药物检测产品的技术进步、加强执行适当的药物筛检相关规则和法规以维持纪律和安全措施等推动的。受多种因素影响。 研发活动投资的增加、多家顶级公司的存在、併购、联盟、分销协议等合资企业以及频繁的新产品发布也进一步加速了全球药物筛选市场的成长。

精神活性物质的消费增加

药物和酒精消费量的增加正在加速药物筛检市场的发展。 焦虑、压力、忧郁、孤立和获得社会支持的机会有限，这些都会导致人们滥用药物。 由于药物过量案例数量不断增加，导致了事故、自我破坏甚至死亡等许多负面后果，因此对药物筛检服务的需求日益增加。 根据《2023年世界毒品报告》，2021年吸毒者总数估计为2.96亿人。 据估计，大麻是全世界人们使用最广泛的药物。 药物滥用的增加给医疗保健系统带来了压力，并凸显了严格药物筛检活动的重要性。 此外，药物筛选在最大限度地减少道路交通事故等事故的发生方面发挥着重要作用，这也是推动市场成长的主要因素。

政府措施

政府透过不断制定政策和计划来监测国内药物滥用案件，在控制和遏制药物滥用方面发挥重要作用。 各国政府参与促进研发活动，开发高效率的药物滥用检测产品和设备。 例如，国家药物滥用研究所是一个联邦机构，致力于支持科学研究以了解和控制药物滥用，重点是推动研发工作以控制全球药物滥用。

对快速测试设备的需求不断增加

以组件来看，快速测试设备越来越受欢迎，预计该行业将以更快的速度成长。 这些设备在市场上被过度使用，因为它们易于管理、成本效益高且能快速产生结果。 由于需求不断增长，几家大公司正在将这种产品添加到他们的产品组合中。

本报告调查了全球药物筛选市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球药物筛选市场展望

  • 市场规模/预测
  • 按组件
    • 快速检测装置
    • 设备
    • 消耗品
    • 实验室服务
  • 依样本类型
    • 呼气
    • 唾液
    • 头髮
    • 尿液
    • 其他
  • 按最终用户
    • 医院
    • 工作场所
    • 药物检测实验室
    • 刑事司法系统/执法机构
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球药物筛选市场前景：依地区划分

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 按组件
  • 按样本
  • 按最终用户
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 专利情况
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • Abbott Laboratories
  • Alfa Scientific Designs Inc.
  • Bio-Rad Laboratories, Inc.
  • Drager Group
  • Thermo Fisher Scientific
  • Siemens Healthineers company
  • Psychemedics Corporation
  • OraSure Technologies, Inc.
  • Omega Laboratories, Inc.
  • Laboratory Corporation of America Holdings

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11136

Global drug screening market is projected to witness a CAGR of 14.65% during the forecast period 2024-2031, growing from USD 7.02 billion in 2023 to USD 20.96 billion in 2031. Growth in the global drug screening market is driven by various factors, such as increasing alcohol and drug consumption, technological advancements in drug testing products, and increased implementation of strict rules and regulations regarding proper drug screening among the people to maintain discipline and safety measures. Growing investments in research and development activities, presence of several top players, and collaborative ventures, such as mergers and acquisitions, partnerships, distribution agreements, and frequent new product launches, further accelerate the growth of the global drug screening market.

The global drug screening market is experiencing tremendous growth due to various key factors. One of the primary drivers is the increasing global consumption of drugs and alcohol, leading to an increased demand for drug screening services worldwide. Stringent regulations frameworks to enhance drug and alcohol testing are fueling the market's expansion. Additionally, excessive drug abuse leads to a rising burden of accidents, which has further accelerated the need for developing effective drug screening solutions. Government initiatives and support, such as granting funds, to manage and monitor drug abuse play a pivotal role in propelling market growth. The presence of key market players, along with continuous technological advancements in drug screening products, are enhancing their efficiency and effectiveness, thereby driving demand for more advanced solutions. Moreover, collaboration activities, such as mergers and acquisitions, distribution agreements, and partnerships, further accelerate growth of the global drug screening market.

For instance, in January 2024, OraSure Technologies, Inc., which is a global leader in diagnostics, announced that it has signed a distribution agreement with Sapphiros, which is a Boston-based diagnostics company. Through this strategic partnership, OraSure expects to develop cost-effective diagnostics tests and enhance its product portfolio, as well as expand its business globally.

Increasing Consumption of Psychoactive Substances

The increased consumption of drugs and alcohol is accelerating the drug screening market. Anxiety, stress, depression, isolation, and limited access to social help have contributed to higher drug abuse among the population. Rising cases of drug overdose, which leads to many adverse effects, such as accidents, self-destruction activities, and even death, have surged the need for drug screening services. For instance, according to World Drug Report 2023, the total number of drug users in the year 2021 was estimated to be 296 million. It is also estimated that cannabis is the most widely used drug by the population across the globe. This increasing drug abuse led to the global burden on health and health-care systems, emphasizing the importance of following strict drug screening activities. Additionally, drug screening plays an essential role in minimizing the growing cases of accidents, such as road traffic accidents, which is acting as a major factor flourishing the market growth.

Government Initiatives

The government plays a crucial role in managing and controlling the increased prevalence of drug abuse by continuously developing policies and programs to monitor drug abuse cases within the country. The government is involved in promoting research and development activities to develop highly efficient drug abuse detection products and devices. For instance, the National Institute on Drug Abuse, which is a federal agency that works on supporting scientific research on understanding and controlling drug abuse, emphasizes on promoting research and development activities to control global drug abuse. The federal agency brings concerns on various aspects of drug abuse, such as developing drug testing kits that can efficiently and accurately detect alcohol and drug consumption. Due to these frequent governmental support and initiatives, public and private diagnostics companies are excessively involved in developing innovative drug screening products and have increased investment activities, which is further improving the overall global drug screening market.

Increased Demand for Rapid Testing Devices

Among the component segment, rapid testing devices are gaining popularity, due to which this segment is expected to grow at a faster pace in the global drug screening market. These devices are easy to administer, are cost-effective, and give faster results due to which they are excessively used in the market. As the demand is rising, several leading players are launching this product in their product portfolio. For instance, in April 2023, MIP Discovery, which is a pioneer in developing reagents, announced the launch of "Novel nanoMIPTM affinity reagents" using its proprietary nanoMIPTM technology to detect opioid. This reagent is highly sensitive and robust in detecting opioid consumption. These latest launches by key companies in this segment are expected to enhance growth in the global drug screening market.

Growing Demand for Oral Fluid Samples-based Testing Kits

Among the sample type segment, oral fluids, such as saliva-based samples, are expected to show significant growth in the future. There have been increased investments and research and development activities to develop oral fluid sample-based diagnostics kits by several leading players, which is accelerating market growth. For instance, Alfa Scientific Designs Inc., which is a global leader in the development and manufacturing of rapid immunoassay point-of-care tests, states in its latest article that saliva testing has gained tremendous growth over the past few years. Several rapid diagnostic test manufacturers have claimed that saliva samples give faster results compared to other samples. Additionally, saliva samples possess several benefits over other samples as they can be done anywhere, anytime, do not require other tools and appliances for data collection, and do not have any privacy issue. Due to these potential benefits of saliva-based tests, several leading players prefer to invest in developing diagnostics kits that use saliva samples to detect drug abuse, further enhancing their product portfolio and leading to the growth of global drug screening market.

North America Holds the Maximum Share in the Market

North America dominates the global drug screening market due to its robust healthcare system and implementation of strict rules and regulations regarding drug abuse. The availability of technologically advanced drug screening kits and their high efficiency in detecting drug usage further propels the drug screening market in the region. Additionally, the increasing prevalence of drug abuse in the United States is compelling the requirement for efficient drug screening products, thereby significantly impacting the market growth. For instance, according to the U.S. National Center for Drug Abuse Statistics, around 19.4% of U.S population have used illegal drugs at least once in the year 2021. Additionally, The Journal of the American Medical Association report also states that between January 2021 and June 2021, approximately 1,150 youngsters within the age group of 14 to 18 died from drug overdose. Due to this increasing number of people involved in excessive drug and alcohol consumption, there has been a substantial need for drug screening activities to combat the increasing number of drug abuse cases in the region.

Future Market Scenario (2024 - 2031F)

The global drug screening market is expected to grow in the future, primarily due to increased global consumption of drugs and alcohol, stringent rules and regulations on drug testing, and government initiatives and support to combat drug abuse. Additionally, technological advancements and increased investments by public and private diagnostics manufacturers will lead to the development of more efficient drug screening products, thereby creating lucrative market opportunities. Moreover, favorable regulatory frameworks that help in faster FDA approvals, while maintaining the accuracy and efficacy of the drug testing devices, further accelerate the growth of the global drug screening market.

Key Players Landscape and Outlook

In the drug screening market, several leading players are frequently undergoing strategic partnerships and distribution agreements, which play a pivotal role in propelling the global drug screening market's expansion. These partnership agreements empower companies to gain informative insights regarding the latest trends in the market, access each other's resources, and technologies, and invest in research and development activities to enhance and innovate product offerings. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expertise product development, and contribute to the enduring and tremendous growth of the global market. For instance, in February 2023, Omega Laboratories, which is a global leader in providing laboratory testing solutions, announced that it has established a strategic partnership with Life Diagnostics, which is among the UAE's fastest-growing company in diagnostics. This partnership aims to establish a new drugs of abuse testing laboratory in the country, which is expected to lead the growth of the Middle East and Africa region in the global drug screening market.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Drug Screening Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Components
    • 4.2.1.Rapid Testing Devices
      • 4.2.1.1.Urine Testing Devices
      • 4.2.1.2.Oral Fluid Testing Devices
    • 4.2.2.Equipment
      • 4.2.2.1.Breath Analyzers
      • 4.2.2.2.Immunoassay Analyzers
      • 4.2.2.3.Chromatography Instruments
    • 4.2.3.Consumables
      • 4.2.3.1.Assay Kits
      • 4.2.3.2.Sample Collection Cups
      • 4.2.3.3.Calibrators and Controls
      • 4.2.3.4.Others
    • 4.2.4.Laboratory Services
  • 4.3.By Sample Type
    • 4.3.1.Breath
    • 4.3.2.Oral Fluid
    • 4.3.3.Hair
    • 4.3.4.Urine
    • 4.3.5.Others
  • 4.4.By End-user
    • 4.4.1.Hospital
    • 4.4.2.Workplaces
    • 4.4.3.Drug Testing Laboratories
    • 4.4.4.Criminal Justice System and Law Enforcement Agencies
    • 4.4.5.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Drug screening Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Components
      • 5.1.2.1.Rapid Testing Devices
      • 5.1.2.1.1.Urine Testing Devices
      • 5.1.2.1.2.Oral Fluid Testing Devices
      • 5.1.2.2.Equipment
      • 5.1.2.2.1.Breath Analyzers
      • 5.1.2.2.2.Immunoassay Analyzers
      • 5.1.2.2.3.Chromatography Instruments
      • 5.1.2.3.Consumables
      • 5.1.2.3.1.Assay Kits
      • 5.1.2.3.2.Sample Collection Cups
      • 5.1.2.3.3.Calibrators and Controls
      • 5.1.2.3.4.Others
      • 5.1.2.4.Laboratory Services
    • 5.1.3.By Sample Type
      • 5.1.3.1.Breath
      • 5.1.3.2.Oral Fluid
      • 5.1.3.3.Hair
      • 5.1.3.4.Urine
      • 5.1.3.5.Others
    • 5.1.4.By End-user
      • 5.1.4.1.Hospital
      • 5.1.4.2.Workplaces
      • 5.1.4.3.Drug Testing Laboratories
      • 5.1.4.4.Criminal Justice System and Law Enforcement Agencies
      • 5.1.4.5.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Components
      • 5.1.5.2.1.Rapid Testing Devices
      • 5.1.5.2.1.1.Rapid Testing Devices
      • 5.1.5.2.1.2.Urine Testing Devices
      • 5.1.5.2.1.3.Oral Fluid Testing Devices
      • 5.1.5.2.2.Equipment
      • 5.1.5.2.2.1.Breath Analyzers
      • 5.1.5.2.2.2.Immunoassay Analyzers
      • 5.1.5.2.2.3.Chromatography Instruments
      • 5.1.5.2.3.Consumables
      • 5.1.5.2.3.1.Assay Kits
      • 5.1.5.2.3.2.Sample Collection Cups
      • 5.1.5.2.3.3.Calibrators and Controls
      • 5.1.5.2.3.4.Others
      • 5.1.5.2.4.Laboratory Services
      • 5.1.5.3.By Sample Type
      • 5.1.5.3.1.Breath
      • 5.1.5.3.2.Oral Fluid
      • 5.1.5.3.3.Hair
      • 5.1.5.3.4.Urine
      • 5.1.5.3.5.Others
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospital
      • 5.1.5.4.2.Workplaces
      • 5.1.5.4.3.Drug Testing Laboratories
      • 5.1.5.4.4.Criminal Justice System and Law Enforcement Agencies
      • 5.1.5.4.5.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Components
  • 6.2.By Sample Type
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Abbott Laboratories
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Alfa Scientific Designs Inc.
  • 13.3.Bio-Rad Laboratories, Inc.
  • 13.4.Drager Group
  • 13.5.Thermo Fisher Scientific
  • 13.6.Siemens Healthineers company
  • 13.7.Psychemedics Corporation
  • 13.8.OraSure Technologies, Inc.
  • 13.9.Omega Laboratories, Inc.
  • 13.10.Laboratory Corporation of America Holdings

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 4.Global Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 5.Global Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Drug Screening Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 10.North America Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 11.North America Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Drug Screening Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 16.United States Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 17.United States Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 21.Canada Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 22.Canada Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 26.Mexico Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 27.Mexico Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 31.Europe Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 32.Europe Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Drug Screening Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 37.Germany Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 38.Germany Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 42.France Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 43.France Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 47.Italy Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 48.Italy Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 52.United Kingdom Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 53.United Kingdom Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 57.Russia Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 58.Russia Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 62.Netherlands Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 63.Netherlands Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 67.Spain Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 68.Spain Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 72.Turkey Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 73.Turkey Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 77.Poland Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 78.Poland Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 82.South America Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 83.South America Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Drug Screening Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 88.Brazil Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 89.Brazil Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 93.Argentina Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 94.Argentina Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 98.Asia-Pacific Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 99.Asia-Pacific Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Drug Screening Market Share (%), By Country, 2017-2031F
  • Figure 101.India Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 104.India Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 105.India Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 109.China Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 110.China Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 114.Japan Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 115.Japan Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 119.Australia Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 120.Australia Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 124.Vietnam Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 125.Vietnam Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 129.South Korea Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 130.South Korea Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 134.Indonesia Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 135.Indonesia Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 139.Philippines Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 140.Philippines Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 144.Middle East & Africa Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 145.Middle East & Africa Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Drug Screening Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 150.Saudi Arabia Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 151.Saudi Arabia Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 155.UAE Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 156.UAE Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Drug Screening Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Drug Screening Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Drug Screening Market Share (%), By Components, 2017-2031F
  • Figure 160.South Africa Drug Screening Market Share (%), By Sample Type, 2017-2031F
  • Figure 161.South Africa Drug Screening Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Components Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023